<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04682678</url>
  </required_header>
  <id_info>
    <org_study_id>38RC20.165</org_study_id>
    <nct_id>NCT04682678</nct_id>
  </id_info>
  <brief_title>Spinal Cord Stimulation for Gait Disorders in Parkinson's Disease</brief_title>
  <acronym>SCM-PARK</acronym>
  <official_title>Spinal Cord Stimulation for Gait Disorders in Parkinson's Disease: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our project is based on the fundamental hypothesis that epidural spinal cord stimulation&#xD;
      (SCS) improves Freezing of gait (FOG) in patients with Parkinson's disease. In eight patients&#xD;
      implantation of electrodes for SCS at the epidural thoracic level will be performed under&#xD;
      general anaesthesia.&#xD;
&#xD;
      Evaluation of gait and motor symptoms will be performed with and without stimulation, after a&#xD;
      3-month period for each of the stimulation conditions.This is a pilot, single centre,&#xD;
      prospective, randomized, double blinded, cross-over study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be selected in the Movement Disorders Unit, Department of Neurology, University&#xD;
      Hospital Grenoble. A preoperative assessment with gait assessment, clinical evaluation and&#xD;
      Non-Motor Symptoms assessment will be realized. The implantation of electrodes for SCS at the&#xD;
      epidural thoracic level connected to a neurostimulator at the abdominal level will be&#xD;
      performed under general anaesthesia. During the first postoperative month, the optimization&#xD;
      of SCS parameters will be performed by an experienced movement disorders neurologist.After&#xD;
      the first post-operative month the patient will be randomized to the STIM ON condition&#xD;
      (stimulation on, with the most effective parameters) or STIM OFF (without stimulation). The&#xD;
      randomization will be performed in a double blinded fashion, by a neurologist working in open&#xD;
      and not participating in the evaluations. After 3 months, the patient will be evaluated in a&#xD;
      double blind condition, and the stimulation condition will be crossed for another period of 3&#xD;
      months. At the end of this second 3-month period, the patient will be again double-blind&#xD;
      assessed. After this evaluation, the patient will enter the open phase of the study for a&#xD;
      period of 6 months. For this last phase of the study, under STIM ON condition, an&#xD;
      optimization of the stimulation settings will be realized, if necessary. At the end of this&#xD;
      6-month period of stimulation, the patient will be evaluated one last time. At all visits,&#xD;
      clinical and gait evaluations will be carried out under chronic dopaminergic treatment. No&#xD;
      change in antiparkinsonian treatment will be allowed during the entire study. Gait and&#xD;
      clinical assessment will be performed at baseline and at the end of each double blinded phase&#xD;
      and at 1-year follow-up. For the double-blind study the patient, the neurologist who performs&#xD;
      the clinical evaluation and the expert who performs the gait test and analysis will be blind&#xD;
      to the stimulation condition.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 29, 2021</start_date>
  <completion_date type="Anticipated">January 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 28, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>frequency and duration of Freezing Of Gait (FOG) episodes, objective</measure>
    <time_frame>Month 6</time_frame>
    <description>gait testing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>frequency and duration of Freezing Of Gait (FOG) episodes, subjective 1</measure>
    <time_frame>Month 12</time_frame>
    <description>New FOG-questionnaire (NFOG-Q)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>frequency and duration of Freezing Of Gait (FOG) episodes, subjective 2</measure>
    <time_frame>Month 12</time_frame>
    <description>patient diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>impact of spinal cord stimulation on FOG, long term outcome</measure>
    <time_frame>Month 12</time_frame>
    <description>New Freezing Of Gait-questionnaire (NFOG-Q)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>impact of spinal cord stimulation on quality of life, long term outcome</measure>
    <time_frame>Month 12</time_frame>
    <description>Parkinsons disease questionnaire (PDQ39)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>impact of SCS on gait during a dual cognitive-motor task test</measure>
    <time_frame>Month 12</time_frame>
    <description>New FOG-questionnaire (NFOG-Q)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>impact of SCS on other non-motor symptoms</measure>
    <time_frame>Month 12</time_frame>
    <description>SCales for Outcomes in PArkinson's disease - Autonomic Dysfunction (SCOPA-AUT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>impact of SCS on gait during timed up and go test</measure>
    <time_frame>Month 12</time_frame>
    <description>timed up and go test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Parkinson Disease</condition>
  <condition>Gait Disorders, Neurologic</condition>
  <arm_group>
    <arm_group_label>OFF STIM</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>without stimulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ON STIM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>stimulation with the most effective parameters</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Implantation of electrodes for Spinal cord stimulation</intervention_name>
    <description>The implantation of electrodes for SCS at the epidural thoracic level connected to a neurostimulator at the abdominal level will be performed under general anaesthesia (hospitalization for 3 days in the Neurosurgery Department, CHUGA) in a maximum delay of 1 month following the preoperative assessment. During the first postoperative month, the optimization of SCS parameters will be performed by an experienced movement disorders neurologist.</description>
    <arm_group_label>OFF STIM</arm_group_label>
    <arm_group_label>ON STIM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Patients with diagnosis of idiopathic PD&#xD;
&#xD;
          2. Aged 50-85 years&#xD;
&#xD;
          3. Having a FOG (score&gt; 14 at New-FOG-Questionnaire; score&gt; = 1 at item 2.13 of the&#xD;
             Movement Disorders Society-Unified Parkinson's Disease Rating Scale) despite the&#xD;
             optimization of medical treatment&#xD;
&#xD;
          4. Drug treatment stable for at least 2 months&#xD;
&#xD;
          5. Able to give written consent.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Pain syndrome (score&gt; = 2 at item 1.9 of the MDS-UPDRS II)&#xD;
&#xD;
          2. Psychosis&#xD;
&#xD;
          3. Severe depression&#xD;
&#xD;
          4. Severe cognitive impairment (Mini Mental Score Examination &lt;19)&#xD;
&#xD;
          5. Patient receiving STN DBS treatment&#xD;
&#xD;
          6. Presence of other neurological or medical pathologies interfering with walking&#xD;
&#xD;
          7. Subject in period of exclusion from another study&#xD;
&#xD;
          8. Subject under administrative or judicial supervision&#xD;
&#xD;
          9. Subject who cannot be contacted in an emergency.&#xD;
&#xD;
         10. Person with any administrative or judicial measure of deprivation of rights and&#xD;
             liberty&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elena MORO</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHUGA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrea KISTNER</last_name>
    <phone>**33</phone>
    <phone_ext>476767575</phone_ext>
    <email>akistner@chu-grenoble.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chu Grenoble Alpes</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>KISTNER Andr√©a</last_name>
      <phone>33 (0)4 76 76 94 59</phone>
      <email>AKistner@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>MORO Elena</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 8, 2020</study_first_submitted>
  <study_first_submitted_qc>December 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2020</study_first_posted>
  <last_update_submitted>January 29, 2021</last_update_submitted>
  <last_update_submitted_qc>January 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
    <mesh_term>Gait Disorders, Neurologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

